| 13th week of 2009 patent applcation highlights part 47 |
| Patent application number | Title | Published |
|---|
| 20090082302 | MODULATION OF EIF4E-BP2 EXPRESSION - Compounds, compositions and methods are provided for modulating the expression of eIF4E-BP2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding eIF4E-BP2. Methods of using these compounds for modulation of eIF4E-BP2 expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E-BP2 are provided. | 2009-03-26 |
| 20090082303 | DRUG FOR PREVENTING AND TREATING ATHEROSCLEROSIS - The present invention relates to a prophylactic/therapeutic agent for atherosclerosis comprising GM3 synthase inhibitor or inhibitor for expression of GM3 synthase gene, a diagnostic product for atherosclerosis comprising antibody to GM3 synthase, a method of diagnosis for atherosclerosis using antibody to GM3 synthase and others, an use of GM3 or GM3 synthase for diagnostic marker of atherosclerosis, and the like. | 2009-03-26 |
| 20090082304 | Methods of Treating Hematological Malignancies with Nucleoside Analog Drugs - The present invention provides methods of treating hematological malignancies, including multi-drug resistant malignancies, with 8-amino-adenosine and variants thereof. Also encompassed by the present invention is a method of predicting the response of a patient diagnosed with a hematological malignancy to treatment with a nucleoside analog and a method of screening candidate drugs for efficacy in treating hematological malignancies. | 2009-03-26 |
| 20090082305 | METHOD OF IMPROVING STORAGE STABILITY OF SUBSTANCE - The present invention relates to a method of improving storage stability of reduced form of nicotinamide adenine dinucleotide, reduced form of nicotinamide adenine dinucleotide phosphate, or a salt thereof, or ascorbic acid, an ascorbic acid derivative, or a salt thereof, which comprises allowing the substance to coexist with an L-arginine acidic amino acid salt, a composition containing the substance and an L-arginine acidic amino acid salt, a process for producing the composition, and a method of storing the substance in the presence of an L-arginine acidic amino acid salt. | 2009-03-26 |
| 20090082306 | DEUTERIUM-ENRICHED TELBIVUDINE - The present application describes deuterium-enriched telbivudine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082307 | METHOD FOR PRODUCING OLIGOPOLYSACCHARIDES - The invention concerns the production by microbiological process of oligopolysaccharides of biological interest. More particularly, the invention concerns a method for synthesizing in vivo the oligopolysaccharides by internalization of an exogenous precursor in growing bacterial cells expressing adequate modifying and glycosylating genes. | 2009-03-26 |
| 20090082308 | Benzothiophene derivatives - The present invention relates to a novel class of benzothiophene amide derivatives. The hydroxamic acid compounds can be used to treat cancer. The benzothiophene amide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo. | 2009-03-26 |
| 20090082309 | Method of Regulating Glucose Metabolism, and Reagents Related Thereto - The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis. | 2009-03-26 |
| 20090082310 | PRODRUGS OF THYROID HORMONE ANALOGS - Provided herein are compounds of the formula (I): | 2009-03-26 |
| 20090082311 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes - The present invention provides a novel compound having few side effects such as bradycardia and the like and having superior peripheral blood lymphocyte-decreasing effect. | 2009-03-26 |
| 20090082312 | DEUTERIUM-ENRICHED ZOLEDRONIC ACID - The present application describes deuterium-enriched zoledronic acid, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082313 | Multikinase Inhibitors for Use in the Treatment of Cancer - The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): | 2009-03-26 |
| 20090082314 | Targeting Prodrugs for the Treatment of Gastrointestinal Diseases - Provided herein are compounds, compositions and methods for decreasing NFκB DNA-binding activity in a patient comprising administering of a therapeutically effective amount of a compound or composition of the application to the patient to reduce, alleviate or treat various gastrointestinal diseases, such as inflammatory bowel disease (IBD). | 2009-03-26 |
| 20090082315 | Compositions and Methods for Controlling Cholesterol Levels - New compositions and methods are provided for controlling cholesterol levels. The present compositions are uniquely structured to allow a subject to whom the compositions, in the form of unit dosage forms, are administered to benefit from both a statin, such as atorvastatin, and niacin. | 2009-03-26 |
| 20090082316 | Composition and Method Of Stabilized Sensitive Ingredient - The present invention comprises a method of achieving ingredient stabilization in a composition comprising the steps of: combining a pregelatinized starch with at least one sensitive ingredient; adsorbing said sensitive ingredient onto the pregelatinized starch; and wherein said sensitive ingredient is evenly distributed throughout said pregelatinized starch. | 2009-03-26 |
| 20090082317 | LOW-CALCEMIC 16,23-DIENE 25-OXIME ANALOGS OF 1ALPHA,25-DIHYDROXY VITAMIN D3 - The present invention provides novel 16,23-diene 25-oxime ether analogs of 1,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the novel compound of the invention are useful for treating diseases which benefit from a modulation of the levels of 1,25-dihydroxy vitamin D3, for example, cell-proliferative disorders. | 2009-03-26 |
| 20090082318 | DEUTERIUM-ENRICHED MOMETASONE - The present application describes deuterium-enriched mometasone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082319 | DEUTERIUM-ENRICHED BUDESONIDE - The present application describes deuterium-enriched budesonide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082320 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators - Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents. | 2009-03-26 |
| 20090082321 | STEROID CONTAINING DRUG DELIVERY SYSTEMS - Pharmaceutical composition for intraocular use comprising a glucocorticoid derivative, such as beclomethasone 17,21-diproprionate admixed with a biodegradable polymer such as a poly(lactide-co-glycolide) polymer or a high molecular weight polymeric hyaluronic acid are disclosed. | 2009-03-26 |
| 20090082322 | Gender Differences in Experimental Aortic Aneurysm Formation - The present invention generally relates to the relevance of gender differences on abdominal aortic aneurysm (AAA) formation and to methods of inhibiting, preventing, and/or treating AAA formation by administering estrogen, and estrogen derivative, and/or estrogen receptor agonist, to an organism in need thereof. | 2009-03-26 |
| 20090082323 | DEUTERIUM-ENRICHED FULVESTRANT - The present application describes deuterium-enriched fulvestrant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082324 | Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates - The present invention is directed to metal chelating conjugates for use as metallopharmaceutical diagnostic or therapeutic agents. Specifically, conjugates of the present invention include one or more carriers, a linker, and metal coordinating moiety comprising a resorcinol, thioresorcinol, or dithioresorcinol derivative through which the metal coordinating moiety is bonded to the linker. | 2009-03-26 |
| 20090082325 | Cefidinir Oral Suspension - The present invention discloses a novel powder for oral suspension of cefdinir. Also disclosed are methods of preparing the suspension and methods of treatment using the suspension. | 2009-03-26 |
| 20090082326 | SOLUBLE DOSAGE FORMS CONTAINING CEPHEM DERIVATIVES SUITABLE FOR PARENTERAL ADMINISTRATION - The present invention relates to new dosage forms of cephem compounds, useful for the treatment of bacterial infections. The dosage forms are stable, exhibit enhanced solubility, and are particularly well suited for, e.g., parenteral administration. | 2009-03-26 |
| 20090082327 | DEUTERIUM-ENRICHED MEROPENEM - The present application describes deuterium-enriched meropenem, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082328 | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity - This invention relates to novel substituted phenylamino-benzene compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients. | 2009-03-26 |
| 20090082329 | Novel Sulphur-Containing Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors - The disclosure relates to compounds of formula (I): | 2009-03-26 |
| 20090082330 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF - Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described. | 2009-03-26 |
| 20090082331 | S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF - The present invention relates to amides that have activity as SIP receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions. | 2009-03-26 |
| 20090082332 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS - The present invention provides compounds of formula (I) | 2009-03-26 |
| 20090082333 | REMEDY FOR XANTHOMA - A preventive/remedy for xanthoma which contains a compound having an inhibitory effect on squalene synthase, its prodrug or its salt. | 2009-03-26 |
| 20090082334 | DEUTERIUM-ENRICHED QUETIAPINE - The present application describes deuterium-enriched quetiapine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082335 | DEUTERIUM-ENRICHED OXCARBAZEPINE - The present application describes deuterium-enriched oxcarbazepine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082336 | mGluR1 Antagonists as Therapeutic Agents - In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J | 2009-03-26 |
| 20090082337 | Compositions Comprising Quinolone and Methods for Treating or Controlling Infections - Compositions for treating or controlling infections comprise a fluoroquinolone having Formulae I-VIII and have a pH in the range from about 3.5 to about 5.5 or from about 10.5 to about 12. Methods for treating or controlling such infection use such compositions. Such compositions and methods can deliver a higher amount of the fluoroquinolone to the affected site. | 2009-03-26 |
| 20090082338 | PREVENTIVE OR REMEDY FOR GLAUCOMA - There is provided a preventive for glaucoma or a preventive or a remedy for ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. A preventive or a remedy for glaucoma comprising a Rho kinase inhibitor and an α | 2009-03-26 |
| 20090082339 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS - The invention relates to azacyclyl-substituted arylthienopyrimidinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one azacyclyl-substituted arylthienopyrimidinone of the invention or its derivative, and the use of the azacyclyl-substituted arylthienopyrimidinones of the invention and their derivatives as MCH antagonists. | 2009-03-26 |
| 20090082340 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I - The present invention discloses and claims methods for the treatment of a patient suffering from a disease or disorder ameliorated by inhibition of casein kinase Iε activity comprising the administration of a compounds of formula (I) and formula (II) | 2009-03-26 |
| 20090082341 | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER - Provided are methods of treating post-traumatic stress disorder with 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide. Also provided are methods of improving resilience with 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide. Also provided are methods of diagnosing post-traumatic stress disorder in a patient. | 2009-03-26 |
| 20090082342 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS - Disclosed herein are isolated forms of the compounds of Formula (I), (II), (III), (IV) and (V), or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, polymorph, or ester thereof. Also disclosed are methods of inhibiting an activity of a serotonin receptor, methods inhibiting an activation of a serotonin receptor, and methods of alleviating or treating various disease conditions and side effects. | 2009-03-26 |
| 20090082343 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF - This invention provides a compound represented by the formula (I): | 2009-03-26 |
| 20090082344 | Methods and systems for treating disease - Methods and systems described herein are applicable to the identification of pathogens, pathogenic variants and applicable treatments or remedies. In some embodiments, the pathogen or pathogens bears a causal relationship to a disease state. | 2009-03-26 |
| 20090082345 | BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS - The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds of general formula (I) can in particular be used for preparing a medicine for cancer treatment. | 2009-03-26 |
| 20090082346 | Substituted Pyrrolo-Pyrazole Derivatives as Kinase Inhibitors - Compounds represented by formula (Ia) or (Ib) and wherein R and R | 2009-03-26 |
| 20090082347 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS - The present invention provides compounds of the following formula and pharmaceutical compositions that are selective antagonists of A | 2009-03-26 |
| 20090082348 | INDAZOLE DERIVATIVES - The present invention provides a compound represented by Formula (I): | 2009-03-26 |
| 20090082349 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS - Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones. | 2009-03-26 |
| 20090082350 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS - Disclosed are heterocylic or heteroaryl compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetic-related diseases. | 2009-03-26 |
| 20090082351 | PESTICIDE PYRIMIDINYLOXY SUBSTITUTED PHENYLAMIDINE DERIVATIVES - The present invention relates to 2,5-disubstituted-4-pyrimidinyl-substituted-phenyl-amidine derivatives of formula (I) in which the substituents are as in the description, notably to 2,5-dialkyl-4-pyrimidinyl-substituted-phenyl-amidine derivatives, their process of preparation, their use as fungicide or insecticide active agents, particularly in the form of fungicide or insecticide compositions, and methods for the control of phytopathogenic fungi or damaging insects, notably of plants, using these compounds or compositions. | 2009-03-26 |
| 20090082352 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME - A compound represented by the following general formula (I), wherein R | 2009-03-26 |
| 20090082353 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS - The present invention provides new method of treatment of epilepsy with non-imidazole alkylamine derivatives that constitute antagonists of the H3-receptors of histamine. | 2009-03-26 |
| 20090082354 | PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF - A pyrazolo[5,1-c][1,2,4]triazine compound of formula A: | 2009-03-26 |
| 20090082355 | Method of Combating Root Weevils - A method of combating root weevils comprising contacting the root weevils or their food supply, habitat, breeding grounds or their locus with a pesticidally effective amount of a compound of the formula (I) wherein W is Cl or CF | 2009-03-26 |
| 20090082356 | Pyrazine Derivatives and Use as P13k Inhibitors - The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries. | 2009-03-26 |
| 20090082357 | Prolyl Hydroxylase Inhibitors - The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I) | 2009-03-26 |
| 20090082358 | Vanilloid receptor ligands and their use in treatments - Bicyclic 3,4-fused piperidine compounds, and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotizing agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders. | 2009-03-26 |
| 20090082359 | 5-PYRIDINONE SUBSTITUTED INDAZOLES - 5-pyridinone substituted indazoles of the formula | 2009-03-26 |
| 20090082360 | Use of tyrosine kinase inhibitors for treating CNS disorders - The present invention relates to a method for treating CNS disorders, more particularly selected from the group consisting of depression, schizophrenia, anxiety, migraine, memory loss, pain and neurodegenerative diseases, comprising administering a compound capable of depleting mast cells to a human in need of such treatment. Such compounds can be chosen from tyrosine kinase inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3. | 2009-03-26 |
| 20090082361 | DEUTERIUM-ENRICHED IMATINIB - The present application describes deuterium-enriched imatinib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082362 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure - Disclosed are diaryl piperazines and related compounds. These compounds are selective modulators of capsaicin receptors, including human capsaicin receptors, that are, therefore, useful in the treatment of a chronic and acute pain conditions, itch and urinary incontinence. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of capsaicin receptors and as standards in assays for capsaicin receptor binding and capsaicin receptor mediated cation conductance. Methods of using the compounds in receptor localization studies are given. | 2009-03-26 |
| 20090082363 | DEUTERIUM-ENRICHED POSACONAZOLE - The present application describes deuterium-enriched posaconazole, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082364 | DEUTERIUM-ENRICHED LEVOCEDTIRIZINE - The present application describes deuterium-enriched levocetirizine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082365 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists - The present invention relates to quinazolinone compounds of the formula | 2009-03-26 |
| 20090082366 | DEUTERIUM-ENRICHED TELAPREVIR - The present application describes deuterium-enriched telaprevir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082367 | TRIAZOLE DERIVATIVE OR A SALT THEREOF - [Problem] To provide a compound which may be used in treating diseases in which 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is concerned, especially diabetes and insulin resistance. | 2009-03-26 |
| 20090082368 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY - Disclosed are compositions which modulate the interaction with nerve growth factor and precursors thereof with neurotrophic receptors. Also disclosed are methods of using the compositions of the invention, including methods of administration. | 2009-03-26 |
| 20090082369 | Pyrrolo[2,3d]pyrimidine compositions and their use - This invention pertains to compounds having the structure: | 2009-03-26 |
| 20090082370 | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents - The invention provides a combination for use as a protein kinase B inhibitor, the combination comprising (or consisting essentially of) an ancillary compound and: (I) a compound of the formula: or salts, solvates, tautomers or N-oxides thereof, wherein R | 2009-03-26 |
| 20090082371 | Treatment of Viral Disease and Cancer With Nf-kappaB Inhibitors - A method using quinazoline derivatives, celastrol, cape, BAY 11-7082, rocaglamide, and 7-Methoxy-5,11,12-trihydroxy-coumestan is administered to a mammal for the treatment and prevention of viral diseases and cancers. The chemical compounds are targeted to inhibit NF-κB transcriptional activity. These treatments for viral diseases, especially for infection caused by HIV, and cancers may be accomplished utilizing quinazoline derivatives, celastrol, cape, BAY 11-7082, rocaglamide, 7-Methoxy-5,11,12-trihydroxy-coumestan, and compounds similar to them alone or in combination with prior art other therapy. | 2009-03-26 |
| 20090082372 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols - The present invention relates to arylmethylene substituted N-Acyl-β-amino alcohols of the formula I | 2009-03-26 |
| 20090082373 | Uses of 2-[piperidinyl]methyl-2, 3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one for providing an analgesic effect, anti-allergic effect and histamine H1 receptor antagonism effect - The present invention discloses new uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one in providing an analgesic effect in a patient, treating passive cutaneous anaphylaxis in a patient, and in eliciting a histamine H | 2009-03-26 |
| 20090082374 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF - The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells. | 2009-03-26 |
| 20090082375 | SOLID FORMS COMPRISING 3-(2,5-DIMETHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME - Provided herein are solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione. Pharmaceutical compositions comprising the solid forms and methods for treating, preventing and managing various disorders are also disclosed. | 2009-03-26 |
| 20090082376 | DEUTERIUM-ENRICHED ALOGLIPTIN - The present application describes deuterium-enriched alogliptin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082377 | Matrix Metalloproteinase Inhibitors - The present invention relates to compounds of Formula (I): | 2009-03-26 |
| 20090082378 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR - This present disclosure relates to compounds of formula (I): | 2009-03-26 |
| 20090082379 | Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors - Compounds of formula (I): | 2009-03-26 |
| 20090082380 | DEUTERIUM-ENRICHED ROSUVASTATIN - The present application describes deuterium-enriched rosuvastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082381 | Percutaneously Absorbable Ophthalmic Preparation - The present invention provides a percutaneously absorbable ophthalmic preparation that permits the retention of a therapeutically effective concentration of a heterocyclic spiro compound and a salt thereof for promoting lacrimation, and that produces less adverse reactions such as miosis. Specifically, the present invention provides a percutaneously absorbable ophthalmic preparation comprising as an active ingredient a heterocyclic spiro compound represented by the general formula (I): | 2009-03-26 |
| 20090082382 | DEUTERIUM-ENRICHED NALTREXONE - The present application describes deuterium-enriched naltrexone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082383 | DEUTERIUM-ENRICHED BUPRENORPHINE - The present application describes deuterium-enriched buprenorphine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082384 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. | 2009-03-26 |
| 20090082385 | DEUTERIUM-ENRICHED DESLORATIDINE - The present application describes deuterium-enriched desloratadine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082386 | Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof - Provided is ascomycin that has a low level of an FK523 impurity, and pimecrolimus that has a low level of a 32-deoxy-32-epichloro-FK523 impurity, methods of preparing them, and the use of such pimecrolimus for preparing a pharmaceutical composition. | 2009-03-26 |
| 20090082387 | DEUTERIUM-ENRICHED NVP-BEZ234 - The present application describes deuterium-enriched NVP-BEZ235, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
| 20090082388 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS - As disclosed herein, co-administration of pimavanserin with an agent that ameliorates one or more cholinergic abnormalities can have a synergistic effect on the efficacy of the agent. Disclosed herein are compositions which include pimavanserin in combination with an agent that ameliorates one or more cholinergic abnormalities. Also disclosed herein are methods for ameliorating or treating a disease condition characterized by one or more cholinergic abnormalities that can include administering pimavanserin in combination with an agent that ameliorates one or more cholinergic abnormalities. | 2009-03-26 |
| 20090082389 | PESTICIDAL SUBSTITUTED PIPERIDINES - The invention relates to the use of piperidine derivatives encompassed from the general formula (I) for the control of pests, including arthropods and helminths, and a method for the control of pests. | 2009-03-26 |
| 20090082390 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST - This invention relates to N-aroyl cyclic amine derivatives and their use as pharmaceuticals, specifically as orexin receptor antagonists. | 2009-03-26 |
| 20090082391 | NOVEL AMINOALCOHOL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS - The invention relates to aminoalcohol-substituted aryldihydroisoquinolinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one aminoalcohol-substituted aryldihydroisoquinolinone of the invention or its derivative, and the use of the aminoalcohol-substituted aryldihydroisoquinolinones of the invention and their derivatives as MCH antagonists. | 2009-03-26 |
| 20090082392 | Substituted Carboxylic Acids - The present invention relates to compounds and pharmaceutically acceptable salts of formula (I): | 2009-03-26 |
| 20090082393 | New addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them - Compounds of formula (I): | 2009-03-26 |
| 20090082394 | Tetrahydroisoquinoline Derivatives to Enhance Memory Function - The invention relates to the use of tetrahydroisoquinoline derivatives for the preparation of a medicament to enhance, maintain and/or restore all stages and/or types of short-, middle- and/or long-term memory. | 2009-03-26 |
| 20090082395 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS - Disclosed are amide, thioamide, urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, and diabetic-related diseases. | 2009-03-26 |
| 20090082396 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS - The invention is directed to 5-(hetero)aryl-4,5-dihydro-(1H)-pyrazole (pyrazoline) derivatives as cannabinoid CB | 2009-03-26 |
| 20090082397 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - This invention provides compounds of formula I: | 2009-03-26 |
| 20090082398 | CRYSTALLINE FORMS OF FEXOFENADINE HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION - Provided are crystalline forms of fexofenadine hydrochloride and processes for their preparation. | 2009-03-26 |
| 20090082399 | Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors - The present invention relates to new compounds which are Carbamate derivatives of formula I wherein X, B, P, Q5W, R | 2009-03-26 |
| 20090082400 | SOLUBLE PYRONE ANALOGS METHODS AND COMPOSITIONS - Methods and compositions are described that comprise pyrone analogs such as flavonoids and cyclodextrins including quercetin and quercetin derivatives and sulfoalkyl ether cyclodextrins. In some cases the compounds of the invention are administered with a therapeutic agent such as an analgesic. In some cases, treatment with the compositions of the invention can result in the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of drugs and other compositions out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide for the increase of efflux transporter activity at blood-brain, blood-CSF and placental-maternal barriers to increase the efflux of drugs and other compositions from physiological compartments, including central nervous system and fetal compartments. | 2009-03-26 |
| 20090082401 | DEUTERIUM-ENRICHED TIAGABINE - The present application describes deuterium-enriched tiagabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-26 |
